EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic Variants of the ATIC Gene and Therapeutic Response to Methotrexate in Patients with Rheumatoid Arthritis

Sergio Gabriel Gallardo-Moya iD, Laura Gonzalez-Lopez iD, Betsabe Contreras-Haro, Mario Alberto Mireles-Ramirez iD, Alejandra Villagomez-Vega iD, María Cristina Morán-Moguel iD, Miriam Méndez-Del Villar iD, María Luisa Vazquez-Villegas, Jorge Ivan Gamez-Nava iD, Ana Miriam Saldaña-Cruz iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26094013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sergio Gabriel Gallardo-Moya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara 4…. Hauptthemen laut MEDLINE: Methotrexate, Arthritis, Rheumatoid, Antirheumatic Agents, Polymorphism, Single Nucleotide. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad de Guadalajara, University of Guadalajara.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methotrexate (MTX) is the conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) recommended as the first-choice anti-rheumatic drug for rheumatoid arthritis (RA). However, responses to MTX may be influenced by genetic variants. We aim to evaluate the association of the rs2372536, rs4673990, and rs4673993 genetic variants of the ATIC gene with therapeutic failure of MTX in patients with RA. A case–control study was performed. Disease activity was measured using the disease activity score based on erythrocyte sedimentation rate (DAS28-ESR). RA patients were classified into two groups: (a) responders (DAS28-ESR ≤ 3.2), which is the group of patients who did respond to methotrexate, and (b) non-responders (DAS28-ESR > 3.2), which is the group of patients who did not respond to methotrexate. Serum levels of the 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) enzyme and Interleukin-6 (IL-6) were quantified using an enzyme-linked immunosorbent assay (ELISA). Genotyping of ATIC genetic variants was performed with quantitative polymerase chain reaction (qPCR) using TaqMan probes. A total of 260 patients with RA were included. In total, 142 (54.6%) were non-responders to MTX. IL-6 levels were increased in the non-responder group (p = 0.002), while no statistical differences were observed in the AICAR levels. The variables associated with non-response were higher HAQ-Di, weekly MTX dose, glucocorticoid use, erythrocyte sedimentation rate, and carriers of the polymorphic homozygous variant of rs4673993 (OR = 4.5, 95% CI: 1.04–19.34; p = 0.04). The use of sulfazaline offered protective effects. Our findings indicate that the polymorphism rs4673993 gene variant of the AICAR protein may significantly influence MTX resistance. Therefore, these results support the importance of the pathway generating extracellular adenosine and its effects on promoting the immune regulation for the mechanism of MTX therapy of RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateArthritis, RheumatoidAntirheumatic AgentsPolymorphism, Single NucleotideNucleotide DeaminasesHumansFemaleMaleMiddle AgedCase-Control StudiesAgedAdultInterleukin-6GenotypeBlood SedimentationTreatment OutcomeAMP Deaminase

Stichwörter der Autor:innen

AICAR transformylaseATIC genemethotrexaterheumatoid arthritistherapeutic response

Substanzen

MethotrexateAntirheumatic AgentsInterleukin-6Nucleotide DeaminasesAMPD1 protein, humanAMP Deaminase

Autor:innen und Institutionen

  • Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
  • Departamento de Fisiología, Instituto de Terapéutica Experimental y Clínica, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
  • Departamento de Ciencias Biomédicas, Centro Universitario de Tonalá (CUT), Universidad de Guadalajara, Tonalá 45425, Jalisco, Mexico.
  • Unidad de Investigación Biomédica 02, Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara 44329, Jalisco, Mexico.
  • Dirección de Investigación y Educación, Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara 44329, Jalisco, Mexico.
  • Departamento de Disciplinas Filosófico, Metodológicas e Instrumentales, Centro Universitario de Ciencias de la Salud (CUCS), Guadalajara 44340, Jalisco, Mexico.

ORCID-Profile: Sergio Gabriel Gallardo-Moya, Laura Gonzalez-Lopez, Mario Alberto Mireles-Ramirez, Alejandra Villagomez-Vega, María Cristina Morán-Moguel, Miriam Méndez-Del Villar, Jorge Ivan Gamez-Nava, Ana Miriam Saldaña-Cruz

Förderung

  • Universidad de Guadalajara
  • University of Guadalajara

Zitieren

APA

Gallardo-Moya, S. G., Gonzalez-Lopez, L., Contreras-Haro, B., Mireles-Ramirez, M. A., Villagomez-Vega, A., Morán-Moguel, M. C., Méndez-Del Villar, M., Vazquez-Villegas, M. L., Gamez-Nava, J. I., & Saldaña-Cruz, A. M. (2025). Genetic Variants of the ATIC Gene and Therapeutic Response to Methotrexate in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094013

Vancouver

Gallardo-Moya SG, Gonzalez-Lopez L, Contreras-Haro B, Mireles-Ramirez MA, Villagomez-Vega A, Morán-Moguel MC, et al. Genetic Variants of the ATIC Gene and Therapeutic Response to Methotrexate in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094013

BibTeX
@article{GallardoMoya2025,
  author = {Gallardo-Moya, Sergio Gabriel and Gonzalez-Lopez, Laura and Contreras-Haro, Betsabe and Mireles-Ramirez, Mario Alberto and Villagomez-Vega, Alejandra and Morán-Moguel, María Cristina and Méndez-Del Villar, Miriam and Vazquez-Villegas, María Luisa and Gamez-Nava, Jorge Ivan and Saldaña-Cruz, Ana Miriam},
  title = {Genetic Variants of the ATIC Gene and Therapeutic Response to Methotrexate in Patients with Rheumatoid Arthritis},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26094013}
}
Kostenlos starten →